Skip to main content
. 2018 Aug 3;12(2):260–268. doi: 10.14444/50323

Figure.

Figure

Kaplan-Meier plot of malignant neoplasia risk in recombinant human bone morphogenic protein (rhBMP)-treated and untreated patients. Through a follow-up period of up to 8 years, patients receiving rhBMP were at similar risk to receive a cancer diagnosis as untreated patients (P = .2687 by log-rank test).